KEYNOTE-189 · 2018 · New England Journal of Medicine
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Pembrolizumab plus chemotherapy improves overall survival in metastatic non-squamous NSCLC without targetable mutations.
Source publication
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Leena Gandhi et al. · New England Journal of Medicine · 2018
Sponsor
Merck Sharp & Dohme LLC
Principal investigator
Medical Director
Population
Non-Small-Cell Lung Carcinoma; n=616
Primary endpoint
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging
Methodology notes
Full methodology is under curation. This project aggregates 3 seeded claims across three temporal layers. The replication spec, pre-registered analysis, and version history will appear here as the project matures.
Funding progress
$916K / $3.0M
31%
Funding displayed here is indicative of collaborator interest. Sciync does not broker money, grants, or securities.
Temporal layers
Published findings under validation
1
Active replication in progress
1
Forecast horizons pending resolution
1